Watching C4 Therapeutics; Hearing Traders Circulating Brookline Capital Out With Note Saying 'FDA-Clearance Of IND Supports Our Outlook That CFT8634 Could Enter The Third-Line NSCLC Market And Could Have Sales Of $1.1B' With Buy Rating And $84 PT
Portfolio Pulse from Happy Mohamed
Brookline Capital has issued a note stating that the FDA-clearance of IND supports their outlook that C4 Therapeutics' CFT8634 could enter the third-line NSCLC market and could have sales of $1.1 billion. They have given C4 Therapeutics a buy rating and a price target of $84.
July 06, 2023 | 2:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
C4 Therapeutics' CFT8634 has received FDA-clearance of IND, which Brookline Capital believes could lead to it entering the third-line NSCLC market with potential sales of $1.1 billion. They maintain a buy rating and a price target of $84 for C4 Therapeutics.
The FDA-clearance of IND for C4 Therapeutics' CFT8634 is a positive development for the company. Brookline Capital's note further boosts the outlook for the company, predicting entry into the NSCLC market and potential sales of $1.1 billion. This, along with the maintained buy rating and price target of $84, is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100